New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.
Endocrine Society Annual Meeting - Cardiometabolic Spotlight
New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.
Advertisement
New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.
Advertisement
Advertisement
Trending on HCPLive
1
Teplizumab Receives Accelerated FDA Approval for Stage 3 T1D in Children
2
FDA Clears First OTC Glucose Monitor for Children
3
The HCPFive: Top News for Healthcare Providers from the Week of 06/07
4
How to Approach Chronic Urticaria from Allergist and Dermatologist Perspectives
5